Edinburgh THE pattern of the urinary excretion of cestrogens, pregnanediol and gonadotrophins throughout nine ovulatory menstrual cycles has been described previously (Brown et al., 1958) . The present communication describes the excretion of these substances by two subjects with dysmenorrhoea and one subject with premenstrual tension, before, during and after treatment with norethisterone or its acetate.
The subjects were healthy and were normally active during the periods of investigation. Rectal temperatures were recorded each morning on awakening. Urinary pregnanediol was estimated by the method of Klopper et al. (1955) and urinary gonadotrophins by the method of . Urinary cestrone, oestradiol and cstriol were measured by the methods of Brown (1955) and Brown et al. (1957) . Urinary metabolites of norethisterone and its esters interfere in these methods causing the cestradiol values by both methods and the cestrone values by the latter method to be high; they do not, however, interfere with the determination of cestriol (Brown and Blair, 1960) .
The first subject, who had regular menstrual cycles with severe menstrual and premenstrual dysmenorrheea, was studied throughout four menstrual cycles. The results are shown in Fig. 1 . During the first cycle in which she did not receive any treatment the levels of aestrogen, pregnanediol and gonadotrophin excretion were within the normal range but there was no rise in gonadotrophin excretion at mid-cycle. The temperature chart was biphasic and there was a gain in weight premenstrually. There was severe dysmenorrhoea for three days premenstrually and menstruation lasted five days.
During the second cycle norethisterone acetate (6 mg per day) was administered orally from the fifth to the twenty-fifth day. The gonadotrophin excretion was similar to that during the first cycle. There was no rise in pregnanediol or aestrogen excretion during the second half of the cycle, although a peak of oestrogen excretion occurred at approximately mid-cycle. The temperature chart remained biphasic and there was a gain in weight premenstrually. There was severe dysmenorrhoea for three days before menstruation and the latter lasted four days. The findings in this cycle are compatible with the view that luteal function but not follicular function was depressed by the administration of norethisterone acetate.
During the third cycle norethisterone acetate (12 mg per day) was administered orally from the fifth to the twenty-fifth day. CEstrogen and pregnanediol excretion remained fairly constant throughout the cycle. Gonadotrophins were excreted throughout the cycle with possibly a peak of excretion about the eighth day. The temperature chart was still biphasic but there was neither dysmenorrheea nor a premenstrual weight gain. The duration of menstrual bleeding was reduced and lasted only three and a half days. The findings in this cycle suggest that both follicular and luteal functions were depressed. It was surprising that the temperature chart in both this and the previous cycle remained biphasic since the administration of norethisterone usually has a hyperthermic effect (Pots, 1957) .
The findings during the fourth cycle where no norethisterone was administered were similar to those in Cycle 1 except for the presence of a peak in gonadotrophin excretion at approximately mid-cycle.
In the other two subjects studied the administration of norethisterone (10 mg per day) or of its acetate (12 mg per day) from the fifth to the twenty-fifth day of the menstrual cycle prevented any rise in cestrogen and pregnanediol excretion.
The excretion of gonadotrophins was not decreased during the period of treatment.
There seems to be no doubt from these results that norethisterone in a sufficiently large dose, administered from the fifth to the twenty-fifth day of the cycle, will prevent the rise in (estrogen and pregnanediol excretion which normally occurs during the luteal phase and the rise in cestrogen excretion which normally occurs during the follicular phase. Smaller doses of norethisterone appear to inhibit the rise in the excretion of cestrogens and pregnanediol during the second half of the cycle without inhibiting the rise in cestrogen excretion during the follicular phase.
The excretion of gonadotrophins continued throughout each cycle and did not appear to be affected by the administration of norethisterone. It might be postulated therefore that norethisterone exerted its effect by a direct action on the ovary rather than through the pituitary. However, it has been shown that norethisterone decreases the gonadotrophin excretion of postmenopausal patients with mammary carcinoma (Douglas et al., 1960) and inhibits the pituitary secretion of gonadotrophins in parabiotic rats (Epstein et al., 1958) .
